Krystal Biotech (KRYS) Competitors

Krystal Biotech (NASDAQ:KRYS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Is KRYS or ASND more profitable?

Krystal Biotech has a net margin of 40.85% compared to Ascendis Pharma A/S's net margin of -54.94%. Krystal Biotech's return on equity of 15.21% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	40.85%	15.21%	13.81%
Ascendis Pharma A/S	-54.94%	N/A	-24.31%

Do analysts prefer KRYS or ASND?

Krystal Biotech currently has a consensus target price of $209.00, suggesting a potential upside of 34.22%. Ascendis Pharma A/S has a consensus target price of $244.36, suggesting a potential upside of 25.56%. Given Krystal Biotech's higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals hold more shares of KRYS or ASND?

86.3% of Krystal Biotech shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer KRYS or ASND?

In the previous week, Krystal Biotech had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Krystal Biotech and 10 mentions for Ascendis Pharma A/S. Krystal Biotech's average media sentiment score of 1.47 beat Ascendis Pharma A/S's score of 1.27 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, KRYS or ASND?

Krystal Biotech has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$290.52M	15.51	$89.16M	$4.92	31.65
Ascendis Pharma A/S	$490.75M	24.28	-$409.12M	-$5.16	-37.72

Which has more volatility & risk, KRYS or ASND?

Krystal Biotech has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Summary

Krystal Biotech beats Ascendis Pharma A/S on 11 of the 16 factors compared between the two stocks.